Hotgen(SH:688068)2022-04-27 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,364,354,033.74, representing an increase of 11.14% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 605,961,546.65, showing a slight increase of 0.77% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 601,801,232.98, with a year-on-year increase of 0.34%[5]. - Net profit for Q1 2022 reached CNY 615,406,620.35, a slight increase from CNY 601,438,086.05 in Q1 2021, representing a growth of 2.1%[23]. - Basic earnings per share for Q1 2022 were CNY 9.74, compared to CNY 9.67 in Q1 2021, indicating a growth of 0.72%[24]. Cash Flow - The net cash flow from operating activities decreased significantly by 94.21%, amounting to CNY 59,688,999.50[5]. - Cash received from sales of goods and services in Q1 2022 was CNY 1,053,296,630.55, down from CNY 1,642,402,332.61 in Q1 2021, a decrease of 35.8%[25]. - The net cash flow from operating activities was ¥59,688,999.50, a significant decrease from ¥1,030,672,959.16 in the previous year[26]. - Total cash inflow from operating activities amounted to ¥1,075,385,948.77, compared to ¥1,654,548,058.28 in the same period last year[26]. - Cash outflow from operating activities totaled ¥1,015,696,949.27, up from ¥623,875,099.12 year-over-year[26]. - The net cash flow from investing activities was -¥568,742,489.11, slightly improved from -¥587,802,887.57 in the previous year[27]. - Cash inflow from investment activities was ¥764,251,057.89, compared to ¥289,205,000.05 in the same period last year[26]. - Cash outflow from investment activities reached ¥1,332,993,547.00, an increase from ¥877,007,887.62 year-over-year[26]. - The net cash flow from financing activities was not reported, indicating no significant changes in financing during the quarter[27]. - The cash and cash equivalents at the end of the period were ¥644,706,803.08, down from ¥825,519,086.32 at the end of the previous year[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,921,780,780.66, reflecting a growth of 7.60% from the end of the previous year[6]. - The company's total assets reached CNY 3,921,780,780.66 in Q1 2022, up from CNY 3,644,844,550.64 in Q1 2021, representing an increase of 7.6%[20]. - The total liabilities decreased to CNY 431,682,883.24 in Q1 2022 from CNY 771,014,749.09 in Q1 2021, a reduction of 44%[20]. - The total equity attributable to shareholders increased to CNY 3,450,350,484.44 in Q1 2022 from CNY 2,843,524,711.02 in Q1 2021, reflecting a growth of 21.3%[20]. - The company's cash and cash equivalents decreased to RMB 651.46 million from RMB 1.16 billion year-over-year[18]. - The company's trading financial assets increased to RMB 1.05 billion from RMB 927.45 million year-over-year[18]. - Accounts receivable increased by 207.30%, attributed to the expansion of the company's sales scale[10]. - Accounts receivable rose significantly to RMB 114.06 million from RMB 37.12 million year-over-year[18]. - Inventory increased to RMB 346.52 million from RMB 258.62 million year-over-year[18]. - The company's non-current assets totaled RMB 1.58 billion, up from RMB 1.13 billion year-over-year[18]. - The company reported a total of 2.34 billion in current assets, down from 2.52 billion year-over-year[18]. Research and Development - Research and development expenses totaled CNY 45,989,803.16, an increase of 160.95% year-on-year, accounting for 3.37% of operating revenue[6]. - Research and development expenses in Q1 2022 were CNY 45,989,803.16, significantly higher than CNY 17,624,052.30 in Q1 2021, marking an increase of 160.5%[22]. Subsidiaries and Market Expansion - The company established a wholly-owned subsidiary, Hotgen Health Inc., in Albany, New York, with a registered capital of $5 million to develop and sell in vitro diagnostic products, aiming to expand its overseas market presence[15]. - The company set up another wholly-owned subsidiary, Beijing Yujing Pharmaceutical Co., Ltd., with a registered capital of RMB 50 million, focusing on the research of live bacteria drugs and their applications in treating various metabolic and immune diseases[15]. Other Notable Information - The company has not disclosed any significant new product launches or technological advancements during this reporting period[15]. - The company reported a significant increase in investment income by 366.88%, primarily due to higher returns from financial products[10]. - The company received tax refunds amounting to ¥13,825,673.96, compared to ¥1,740,366.34 in the previous year[26]. - The company reported a significant increase in cash received from investment recoveries, totaling ¥757,095,040.00, compared to ¥288,000,000.00 in the same period last year[26].